Laurent Chardonnet

Laurent Chardonnet (finance chief) discloses dealings in 3 companies, chiefly Incyte Corp, Prelude Therapeutics Inc and Axcella Health Inc. The record holds 78 filings, for trades running from 20 November 2008 to 23 May 2023.

The open-market side counts 8 purchases for €144k alongside 39 sales for €20.0M. Sales outweigh purchases by €19.8M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 5 share grants and 26 option exercises. Since January 2023: 1 purchase and no sales on the market.

Half of the purchases are above €15k and half below. On 4 out of 6 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. Ninety days after publication, 5 purchases show a median change of -9.2%, with the price up in 40% of them. Past outcomes like these are no guarantee of what comes next.

Most recently, on 25 May 2023, the filings show an open-market purchase worth €26k in Prelude Therapeutics Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.